HIGGINS ARTHUR J
HIGGINS ARTHUR J's purchase track record
HIGGINS ARTHUR J has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/23/2023 | ZBH | $116K | -0.7% | +12.2% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Zimmer Biomet Extends Exclusive Distribution Deal with Think Surgical. Zimmer Biomet has extended its exclusive distribution agreement with Think Surgical to supply the wireless TMINI miniature robotic system. The deal expands the company's reach in surgical robotics and aligns with its strategy of partnering with innovative technology providers. It follows strong Q2 results that benchmarked well against peers in the surgical equipment sector, reinforcing Zimmer Biomet’s competitive position within the S&P 500.
Transaction History
| ECL | ▲ Buy | Grant | 134 | $0 | 3/31/2025 | View on chart |
| ECL | ▲ Buy | Grant | 124 | $31K | 3/31/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 1,800 | $473K | 2/13/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 1,800 | $259K | 2/13/2025 | View on chart |
| ECL | ▲ Buy | Grant | 133 | $31K | 12/31/2024 | View on chart |
| ECL | ▲ Buy | Grant | 144 | $0 | 12/31/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,000 | $251K | 11/13/2024 | View on chart |
| ECL | ▼ Sell | Open Market | 2,000 | $500K | 11/13/2024 | View on chart |
| ECL | ▲ Buy | Grant | 133 | $0 | 9/30/2024 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $31K | 9/30/2024 | View on chart |
| ECL | ▲ Buy | Grant | 141 | $0 | 6/30/2024 | View on chart |
| ECL | ▲ Buy | Grant | 131 | $31K | 6/30/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,200 | $248K | 5/6/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,300 | $265K | 5/6/2024 | View on chart |
| ECL | ▼ Sell | Open Market | 4,500 | $1.0M | 5/6/2024 | View on chart |
| ECL | ▲ Buy | Grant | 146 | $0 | 3/31/2024 | View on chart |
| ECL | ▲ Buy | Grant | 135 | $31K | 3/31/2024 | View on chart |
| ECL | ▲ Buy | Grant | 157 | $0 | 12/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 151 | $30K | 12/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 184 | $0 | 9/30/2023 | View on chart |
| ECL | ▲ Buy | Grant | 176 | $30K | 9/30/2023 | View on chart |
| ZBH | ▲ Buy | Open Market | 500 | $58K | 8/23/2023 | View on chart |
| ZBH | ▲ Buy | Open Market | 500 | $57K | 8/23/2023 | View on chart |
| ECL | ▲ Buy | Grant | 168 | $0 | 6/30/2023 | View on chart |
| ECL | ▲ Buy | Grant | 161 | $30K | 6/30/2023 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,400 | $252K | 6/13/2023 | View on chart |
| ECL | ▼ Sell | Open Market | 2,400 | $435K | 6/13/2023 | View on chart |
| ECL | ▲ Buy | Grant | 190 | $0 | 3/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 182 | $30K | 3/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 215 | $0 | 12/31/2022 | View on chart |
| ECL | ▲ Buy | Grant | 206 | $30K | 12/31/2022 | View on chart |
| ECL | ▲ Buy | Grant | 214 | $0 | 9/30/2022 | View on chart |
| ECL | ▲ Buy | Grant | 205 | $30K | 9/30/2022 | View on chart |
| ECL | ▲ Buy | Option Exercise | 3,200 | $270K | 8/1/2022 | View on chart |
| ECL | ▼ Sell | Open Market | 3,200 | $534K | 8/1/2022 | View on chart |
| ECL | ▲ Buy | Grant | 205 | $0 | 6/30/2022 | View on chart |
| ECL | ▲ Buy | Grant | 197 | $30K | 6/30/2022 | View on chart |
| ECL | ▲ Buy | Grant | 175 | $0 | 3/31/2022 | View on chart |
| ECL | ▲ Buy | Grant | 168 | $30K | 3/31/2022 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $0 | 12/31/2021 | View on chart |
| ECL | ▲ Buy | Grant | 117 | $27K | 12/31/2021 | View on chart |
| ECL | ▲ Buy | Grant | 130 | $28K | 9/30/2021 | View on chart |
| ECL | ▲ Buy | Grant | 136 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength
Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength. Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.